業績一覧
ACHIEVEMENT LIST
-
Kano S, Kawakita D, Honma Y, Takahashi H, Hanazawa T, Tsukahara K, Fujii S, Okami K, Yamazaki K, Ueki Y, Saito Y, Ozawa H, Imaizumi S, Arai T, Iwaki S, Hanyu K, Yamauchi M, Tanaka R, Yamamura K, Sekimizu M, Fushimi C, Matsuki T, Utsumi Y, Nakaguro M, Nagao T, Tada Y, Multi‐institutional Joint SDC Study Group in Japan: Biomarker-Driven Initial Systemic Therapy Enabling Curative-Intent Treatment in Non-Metastatic Unresectable Salivary Duct Carcinoma: A Multi-Institutional Retrospective Study
Head Neck. 2026 Jul 31, 2026
-
Kano S, Hamada S, Taguchi J, Tsushima N, Idogawa H, Imanari H, Kakumu M, Sakai M, Shimizu Y, Homma A: Histological heterogeneity of SLFN11 expression and its association with response to carboplatin plus paclitaxel therapy in salivary gland cancer
Int J Clin Oncol. 2026 Sep 1, 2026
-
Kano S, Taguchi J, Maeda T, Suzuki T, Hamada S, Kato S, Saito A, Shimizu Y, Homma A: Conversion surgery following trastuzumab and docetaxel combination therapy for unresectable HER2-positive parotid gland cancer
Auris Nasus Larynx. 53(3): 328-331, 2026
-
Fujiwara K, Morita S, Hoshino K, Takeda H, Komatsuda K, Nakamaru Y, Homma A: Comparison of post-operative vestibular function between vestibular schwannoma and non-vestibular schwannoma cerebellopontine angle tumors patients using video head impulse test
J Vestib Res. 36(3): 183-190, 2026
-
Fujiwara K, Morita S, Yanagi H, Hoshino K, Takeda H, Komatsuda K, Nakamaru Y, Furuta Y, Homma A: Psychological outcomes of botulinum toxin treatment for facial nerve palsy sequelae: A retrospective analysis of anxiety and depression
Auris Nasus Larynx. 53(3): 435-440, 2026
-
Fujiwara K, Morita S, Hoshino K, Takeda H, Komatsuda K, Ueda K, Nakamaru Y, Homma A: Safe administration of botulinum neurotoxin type A for facial nerve palsy sequelae in a patient with myasthenia gravis
Auris Nasus Larynx. 53(5): 745-748, 2026
-
Tsushima N, Kano S, Suzuki T, Idogawa H, Kakumu M, Imanari H, Homma A: Resting heart rate as a prognostic indicator for patients with head and neck squamous cell carcinoma
Int J Clin Oncol. 31(7): 1326-1335, 2026
-
Kano S, Kawakita D, Honma Y, Takahashi H, Nakaguro M, Utsumi Y, Saigusa N, Hanazawa T, Tsukahara K, Okada T, Okami K, Yamazaki K, Ueki Y, Saito Y, Ozawa H, Arai T, Shimizu A, Hanyu K, Iwaki S, Imaizumi S, Sakai A, Yamauchi M, Tanaka R, Sato Y, Yamamura K, Sekimizu M, Imanishi Y, Hirai H, Sato Y, Urano M, Yamamoto H, Fushimi C, Matsuki T, Nagao T, Tada Y; Multi-institutional Joint SDC Study Group in Japan: The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy
Oral Oncol. 165:107280, 2025
-
Kano S, Kiyota N, Kinoshita I, Tada Y, Ijichi K, Yamazaki T, Shimizu Y, Hatanaka Y, Tsuda H, Morinaga S, Matsuno Y, Ito YM, Nishimoto N, Kobayashi K, Isoe T, Noguchi T, Homma A, Dosaka-Akita H: Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer
Jpn J Clin Oncol. 55(10): 1131-1140, 2025
-
Kano S, Kinoshita I, Dosaka-Akita H: Author’s reply to “Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer”
Jpn J Clin Oncol. 55(11): 1298, 2025